Catalog No.
KDG93101
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
0.31-5 μg/mL
Sensitivity
0.156 μg/ml
Precision
CV<20%
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Alternative Names
CDX-011 (DOX), CR011, glembatumumab vedotin (ADC), CAS: 1020264-78-1
Background
Glembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’s Xeloda (capecitabine).
Note
For Research Use Only.
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer., PMID:20215530
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer., PMID:20373269
GPNMB expression in uveal melanoma: a potential for targeted therapy., PMID:20375921
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy., PMID:22017590
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer., PMID:22229970
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer., PMID:23874106
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)., PMID:24496926
Novel data in metastatic breast cancer., PMID:24637556
New developments in metastatic breast cancer: integrating recent data into clinical practice., PMID:24892840
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program., PMID:24912408
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma., PMID:25267741
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer., PMID:25267761
Antibody-drug conjugate for advanced melanoma?, PMID:25602109
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer., PMID:25847941
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma., PMID:26305408
Emerging targeted therapies for melanoma., PMID:27148822
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB., PMID:27515299
Antibodies to watch in 2017., PMID:27960628
Novel Targeted Therapies for Metastatic Melanoma., PMID:28114255
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer., PMID:28546082
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent., PMID:29262642
Antibodies to watch in 2018., PMID:29300693
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives., PMID:29439419
Antibody-drug conjugates in triple negative breast cancer., PMID:30175620
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma., PMID:30690710
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives., PMID:31272342
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group., PMID:31586757
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma., PMID:32823698
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study., PMID:34016993
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)., PMID:34590018
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin., PMID:35110681
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic., PMID:35267507
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds., PMID:36160422
ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer., PMID:36900378
For research use only. Not for human or drug use.
